Hemangioma Clinical Trial
Official title:
Clinical Characteristics of Infantile Hemangioma: a Prospective Study
NCT number | NCT03331744 |
Other study ID # | 2017-118 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 6, 2017 |
Est. completion date | December 1, 2025 |
The primary purpose of this study is to identify the clinical characteristics of infantile hemangioma (IH) in our single center in China. The second objective of the study is to identify the clinical features of infantile hepatic hemangioma (IHH) and ulceration in patients with IHs.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A to 6 Years |
Eligibility | Inclusion Criteria: - Age =6 years old - Diagnose of IHs - Consent of both parents (or the person having parental authority in families) Exclusion Criteria: - Congenital hemangioma, kaposiform hemangioendothelioma, or other vascular anomalies - Age>6 years - Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments - Patients with an inability to participate or to follow the study treatment and assessment plan |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Location, size, phase of growth, morphologic subtypes, complication and outcome of IHs in patients. | Clinical characteristics of infantile hemangioma. Phase of growth include proliferation, plateau and involution phase. Morphologic subtypes include localized, segmental, indeterminate and multifocal type. | 2 years | |
Secondary | Demographic information of IH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected. | Demographic characteristics in patients with IH. | 2 years | |
Secondary | Demographic information of IHH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected. | Demographic characteristics in patients with infantile hepatic hemangioma. | 2 years | |
Secondary | Size, type of lesion (focal, multiple and diffuse), complication and outcome of infantile hepatic hemangioma. | Clinical characteristics of infantile hepatic hemangioma | 2 years | |
Secondary | Location, size, complication and outcome in patients with ulcerated IHs. | Clinical characteristics of ulcerated IHs. Phase of growth include proliferation, plateau and involution, and morphologic subtypes include localized, segmental, indeterminate and multifocal type. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01685398 -
Topical Timolol for Superficial Infantile Hemangioma
|
Phase 3 | |
Withdrawn |
NCT00974129 -
A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas
|
N/A | |
Completed |
NCT00374335 -
Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
|
N/A | |
Completed |
NCT02342275 -
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
Completed |
NCT00433940 -
Immune Suppression Of Infants Treated With Steroids
|
N/A | |
Completed |
NCT04065217 -
The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial
|
N/A | |
Terminated |
NCT01743885 -
Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
Terminated |
NCT00555464 -
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
|
Phase 2 | |
Completed |
NCT00394888 -
Hemangioma Associated With High Rates of Morbidity
|
N/A | |
Completed |
NCT05327309 -
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
|
N/A | |
Completed |
NCT02145884 -
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
|
Phase 2 | |
Completed |
NCT04077515 -
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
|
Phase 4 | |
Completed |
NCT02731287 -
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
|
Phase 2 | |
Recruiting |
NCT01147601 -
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
|
Phase 0 | |
Completed |
NCT01908972 -
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
|
Phase 4 | |
Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
Completed |
NCT00001417 -
Direct Injection of Alcohol for the Treatment of Spinal Tumors
|
N/A | |
Completed |
NCT00004436 -
Randomized Study of Hormonal Regulation of Infantile Hemangioma
|
N/A | |
Recruiting |
NCT02496013 -
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
|
Phase 1 | |
Completed |
NCT01072045 -
Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma
|
Phase 2 |